3:43 PM
 | 
Jul 19, 2018
 |  BC Extra  |  Company News

PTC acquiring CNS gene therapy play Agilis

PTC Therapeutics Inc. (NASDAQ:PTCT) will acquire gene therapy company Agilis Biotherapeutics Inc. (Cambridge, Mass.), giving the rare disease company four products in development for CNS disorders.

PTC will pay Agilis shareholders about $200 million up front, including $50 million in cash and about $150 million in PTC stock. Agilis shareholders are also eligible for $745 million in development and sales milestones, plus potential royalties of 2-6%...

Read the full 314 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >